CN105153308A - 针对活化蛋白c的单克隆抗体 - Google Patents

针对活化蛋白c的单克隆抗体 Download PDF

Info

Publication number
CN105153308A
CN105153308A CN201510462991.XA CN201510462991A CN105153308A CN 105153308 A CN105153308 A CN 105153308A CN 201510462991 A CN201510462991 A CN 201510462991A CN 105153308 A CN105153308 A CN 105153308A
Authority
CN
China
Prior art keywords
antibody
apc
monoclonal antibody
activated protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510462991.XA
Other languages
English (en)
Chinese (zh)
Inventor
徐俊
查尔斯·埃斯蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of CN105153308A publication Critical patent/CN105153308A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201510462991.XA 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体 Pending CN105153308A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26
CN2008801210245A CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008801210245A Division CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Publications (1)

Publication Number Publication Date
CN105153308A true CN105153308A (zh) 2015-12-16

Family

ID=40289112

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510462991.XA Pending CN105153308A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN2013101082220A Pending CN103232541A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN2008801210245A Pending CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2013101082220A Pending CN103232541A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
CN2008801210245A Pending CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR20150092358A (enExample)
CN (3) CN105153308A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109897108A (zh) * 2019-03-11 2019-06-18 丁衡 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN113196059A (zh) * 2018-10-18 2021-07-30 俄克拉荷马医学研究基金会 表征疾病活动性的系统性红斑狼疮(sle)疾病活动性免疫指数的生物标志物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801362B2 (en) * 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
CN104936618A (zh) 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途
MX2015006424A (es) * 2012-11-29 2015-08-14 Bayer Healthcare Llc Anticuerpos monoclonales contra una proteina activada c (apc).
TWI673063B (zh) * 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019009407A1 (ja) * 2017-07-07 2019-01-10 第一三共株式会社 抗プロテインｃ抗体
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
EP3682247B1 (en) * 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
KR20240152428A (ko) * 2022-03-04 2024-10-21 주식회사 코애귤런트테라퓨틱스 활성화된 단백질 c에 대한 인간 항체 및 이의 용도
CN119136834A (zh) * 2022-03-04 2024-12-13 凝血剂治疗公司 针对活化蛋白c的骆驼科动物抗体及其用途
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOGNOT D等: "Identification of protein C epitopes altered during its nanoencapsulation", 《JOURNAL OF PROTEIN CHEMISTRY》 *
MOSNIER LO等: "Activated protein C variants with normal cytoprotective but reduced anticoagulant activity", 《BLOOD》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113196059A (zh) * 2018-10-18 2021-07-30 俄克拉荷马医学研究基金会 表征疾病活动性的系统性红斑狼疮(sle)疾病活动性免疫指数的生物标志物
CN109897108A (zh) * 2019-03-11 2019-06-18 丁衡 抗人内皮蛋白c受体的羊驼单域抗体及应用

Also Published As

Publication number Publication date
IL220622A0 (en) 2012-08-30
US8153766B2 (en) 2012-04-10
AU2008316661B2 (en) 2013-05-23
EP2205638A2 (en) 2010-07-14
US20090110683A1 (en) 2009-04-30
US20120164150A1 (en) 2012-06-28
CA2703738C (en) 2018-02-27
KR20150092358A (ko) 2015-08-12
JP2013049694A (ja) 2013-03-14
AU2008316661A1 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
KR101856210B1 (ko) 2018-05-09
JP2014237651A (ja) 2014-12-18
CA2703738A1 (en) 2009-04-30
EP2205638B1 (en) 2017-03-01
US20150344588A1 (en) 2015-12-03
ZA201105704B (en) 2014-05-28
US9127072B2 (en) 2015-09-08
CN101918453A (zh) 2010-12-15
RU2012150953A (ru) 2014-06-10
JP6117741B2 (ja) 2017-04-19
RU2010121148A (ru) 2011-12-10
WO2009055669A2 (en) 2009-04-30
BRPI0818865A2 (pt) 2015-05-05
JP2011500843A (ja) 2011-01-06
IL205284A0 (en) 2010-12-30
WO2009055669A3 (en) 2009-09-03
MX2010004615A (es) 2010-07-06
IL205284A (en) 2014-06-30
CN103232541A (zh) 2013-08-07
RU2539729C2 (ru) 2015-01-27

Similar Documents

Publication Publication Date Title
JP6117741B2 (ja) 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
US11613589B2 (en) Compositions for inhibiting MASP-2 dependent complement activation
JP2021001199A (ja) 発作性夜間血色素尿症の治療のためにｍａｓｐ−１、ｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法
WO2014207199A1 (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
JP2026062897A (ja) 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
TW200407427A (en) Human tissue factor antibodies
HK1196070A (en) Compositions for inhibiting masp-2 dependent complement acitivation
HK1196070B (en) Compositions for inhibiting masp-2 dependent complement acitivation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151216

RJ01 Rejection of invention patent application after publication